Abstract:Since their invention in the early 2000s, tyrosine kinase inhibitors (TKIs) have gained prominence as the most effective pathway-directed anti-cancer agents. TKIs have shown significant utility in the treatment of multiple hematological malignancies and solid tumors, including chronic myelogenous leukemia, non-small cell lung cancers, gastrointestinal stromal tumors, and HER2-positive breast cancers. Given their widespread applications, an increasing frequency of TKI-induced adverse effects has been reported. Although TKIs are known to affect multiple organs in the body including the lungs, liver, gastrointestinal tract, kidneys, thyroid, blood, and skin, cardiac involvement accounts for some of the most serious complications. The most frequently reported cardiovascular side effects range from hypertension, atrial fibrillation, reduced cardiac function, and heart failure to sudden death. The potential mechanisms of these side effects are unclear, leading to critical knowledge gaps in the development of effective therapy and treatment guidelines. There are limited data to infer the best clinical approaches for the early detection and therapeutic modulation of TKI-induced side effects, and universal consensus regarding various management guidelines is yet to be reached. In this state-of-the-art review, we examine multiple pre-clinical and clinical studies and curate evidence on the pathophysiology, mechanisms, and clinical management of these adverse reactions. We expect that this review will provide researchers and allied healthcare providers with the most up-to-date information on the pathophysiology, natural history, risk stratification, and management of emerging TKI-induced side effects in cancer patients.

Advances in the Research of Small Molecule Tyrosine Kinase Inhibitors

Research Progress in the Mechanism of Molecular Targeted Anti-tumor Drugs

Advances in studies of tyrosine kinase inhibitors and their acquired resistance

Discovery of Potent, Orally Active Compounds of Tyrosine Kinase and Serine/Threonine-Protein Kinase Inhibitor with Anti-Tumor Activity in Preclinical Assays

Current Status of Research and Development of New Tyrosine Kinase Inhibitors

Research Progress in Quinazoline Derivatives As Multi-Target Tyrosine Kinase Inhibitors

Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)

Research progress on cardiotoxicity of tyrosine kinase inhibitors(molecular targeting drug)

Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy

The synthesis review of the approved tyrosine kinase inhibitors for anticancer therapy in 2015–2020

Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives

Recent advances in the use of tyrosine kinase inhibitors against thyroid cancer

Development of Egfr Family Small Molecule Inhibitors for Anticancer Intervention: an Overview of Approved Drugs and Clinical Candidates

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective

Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management

Exploring receptor tyrosine kinases-inhibitors in Cancer treatments

Tyrosine kinase inhibitor–induced hypothyroidism: mechanism and clinical implications

Comparative safety and efficacy of tyrosine kinase inhibitors (TKIs) in the treatment setting of different types of leukemia, and different types of adenocarcinoma

Therapeutic advances of targeting receptor tyrosine kinases in cancer

FDA-approved small molecule kinase inhibitors for cancer treatment (2001-2015): Medical indication, structural optimization, and binding mode Part I